Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House May Be Stopping Point For Rx Importation Bills, Hill Staffer Says

Executive Summary

The House could be the last line of defense for blocking prescription drug importation legislation, rather than the Senate, a House subcommittee staffer said Nov. 17 at the Pharmaceutical Regulatory & Compliance Congress in Washington, D.C

You may also be interested in...

GOP Victory Won’t End Rx Import Debate: New Senators Want Open Borders

Seven of the nine new Senators who will join the chamber in January have professed their support for importing prescription drugs into the U.S

Rx Imports: President Bush Says Decision Could Come In December

An announcement on whether the government will allow importation of prescription drugs into the U.S. could come in December, President Bush said during the second presidential debate Oct. 8

Importation Debate Highlights Need For Lower Rx Prices, McClellan Says

The debate over drug importation highlights the need for reduced drug prices, Centers for Medicare & Medicaid Services Administrator Mark McClellan said Aug. 30

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts